Neurol. praxi. 2019;20(2):102-106 | DOI: 10.36290/neu.2019.023

Neurological complications in malaria

MUDr. RNDr. František Stejskal, Ph.D.
Klinika infekčních nemocí 2. LF UK a Nemocnice Na Bulovce, Praha
Infekční oddělení KN Liberec
Ústav imunologie a mikrobiologie 1. LF UK a VFN v Praze

Malaria is distribited in many tropical and subtropical regions, but the risk is highest in sub-Saharan Africa. If untreated, infection
with P. falciparum is a fatal in non-immune travellers. This fact is often neglected, and there are increasing numbers of tourists as
well as Czech workers who travel to high-risk areas without receiving appropriate antimalarial prophylaxis and sufficient information
on the severity, clinical manifestations, diagnosis, and treatment of malaria. Infection with P. falciparum may manifest in more
than one month after returning from a risk area, and P. vivax and P. ovale relapses occurring in months or even years. In the case
of a febrile disease during a stay in or upon return from a malaria region, the infection has to be ruled out by examining stained
blood smears (thick and think blood smear). Treatment must be initiated immediately after diagnosis and is typically provided at
infectious diseases departments, a list of which is available at www.infekce.cz. The combination of artemether and lumefantrine
or that of atovaquone and proguanil is the drug of choice in uncomplicated P. falciparum infection, with mefloquine or quinine
being used only when the above are unavailable. Chloroquine can only be used in non-falciparum infections, and anti-relapse
therapy with primaquine is indicated in tertian vivax and ovale malaria. Malaria prophylaxis is based on preventing mosquito bites
(exposure prophylaxis) and a preventive use of antimalarial drugs (antimalarial chemoprophylaxis) when there is a high risk of malaria. In the Czech Republic, atovaquone/proguanil (Malarone) and doxycycline are available for prophylaxis. The pathogenesis
of tropical malaria is a comprehensive set of processes caused by a production of parasitic antigens and accumulation of P. falciparum
– infected and uninfected red blood cells in many organs. The clinical condition may result in impaired microcirculation,
organ hypoperfusion, tissue hypoxia, and shock with multiple organ failure. Cerebral malaria is the most serious complication that
is manifested by a severe disturbance of consciousness (sopor, coma). The following are thought to be implicated in the pathogenesis
of cerebral malaria: an effect of sequestration of infected red blood cells and obstruction of microcirculatory or a local
production of nitric oxide that can act as a false neurotransmitter, and thus induce encephalopathy. IV artesunate is the drug of
choice in treating cerebral malaria; however, if unavailable in the Czech Republic, IV quinine in combination with IV clindamycin
or doxycycline is used. Supportive treatment of cerebral malaria and other complications in multiple organ failure involves the
use of all available and recommended modalities, similarly to other urgent conditions.

Keywords: Plasmodium falciparum, multiple organ failure, cerebral malaria, quinine, artesunate

Received: March 18, 2019; Accepted: March 18, 2019; Prepublished online: March 18, 2019; Published: April 23, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Stejskal F. Neurological complications in malaria. Neurol. praxi. 2019;20(2):102-106. doi: 10.36290/neu.2019.023.
Download citation

References

  1. Anstey NM, Russel B, Yeo TW, Price RN. The pathophysiology of vivax malaria. Trends Parasitol 2009; 25: 220-226. Go to original source... Go to PubMed...
  2. Ascling HH, Bruneel F, Burchard G, Castelli F, Chiodini PL, Grobusch MP, Lopez-Vélez R, Paul M, Petersen E, Popescu C, Ramharter M, Schlagenhauf P. Management of imported malaria in Europe. Malaria Journal 2012; 11: 328-343. Go to original source... Go to PubMed...
  3. Stejskal F, Nohýnková E, Kosina P, Kulichová J. Diagnostika, léčba a profylaxe malárie. Klin mikrobiol inf lék 2018; 24: 20-30.
  4. Stejskal F. Nové poznatky o patogenezi malárie. Prakt lék 1995; 75: 512-513.
  5. Taylor TE, Rathod PK, Mishra SK, Mohanty S, Arevalo-Herrera M, Duraisingh MT, Smith JD. Investigating the pathogenesis of severe malaria: A multidisciplinary and cross-geographical approach. Am J Trop Med Hyg 2015; 93(Suppl 3): 42-56. Go to original source...
  6. White NJ, PukrittayakameeS, Hien TT, Faiz MA, Mokuolo OA, Dondrop AM. Malaria. Lancet 2014; 383: 723-735. Go to original source...
  7. WHO: World Malaria Report 2018. Dostupný na WWW: http://www.who.int/malaria/publications/world-malaria-report-2018/en/.
  8. WHO: Severe Malaria, Trop Med International Health 2014; 19(Suppl. 1): 7-131. Dostupný na WWW: https://www.who.int/malaria/publications/atoz/severe-malaria-tmih-2014/en/.




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.